MISC

2001年1月

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

LANCET
  • S Nishiguchi
  • ,
  • S Shiomi
  • ,
  • S Nakatani
  • ,
  • T Takeda
  • ,
  • K Fukuda
  • ,
  • A Tamori
  • ,
  • D Habu
  • ,
  • T Tanaka

357
9251
開始ページ
196
終了ページ
197
記述言語
英語
掲載種別
DOI
10.1016/S0140-6736(00)03595-9
出版者・発行元
LANCET LTD

In a prospective randomised controlled study, 90 patients with chronic active hepatitis C and compensated cirrhosis were assigned symptomatic treatment or interferon alfa (IFN-alpha). We report data on decompensation, detection of hepatocellular carcinoma, and mortality rates, IFN-alpha gave a sustained response in only a small proportion of patients, but worsening of compensated cirrhosis was prevented and development of hepatocellular carcinoma was Inhibited, increasing the survival rate. The risk ratio of IFN-alpha versus symptomatic treatment decreased by 0.250 for progression to Child-Pugh grade B, 0.256 for detection of hepatocellular carcinoma, and 0.135 for a fatal outcome.

Web of Science ® 被引用回数 : 193

リンク情報
DOI
https://doi.org/10.1016/S0140-6736(00)03595-9
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000166593700015&DestApp=WOS_CPL

エクスポート
BibTeX RIS